Nuo Therapeutics, Inc. Operating Income Loss

• Nuo Therapeutics, Inc. showed a decrease of -2.4% in Operating Income Loss from 2024 to 2025.
• This data is from Nuo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2010 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2010 to 2025), Nuo Therapeutics, Inc.'s Operating Income Loss has grown by 53.4%.
• Historical annual values: Fiscal year 2025: -$2.52 million | Fiscal year 2024: -$2.46 million | Fiscal year 2023: -$3.17 million | Fiscal year 2022: -$3.32 million | Fiscal year 2021: -$90.7 thousand | Fiscal year 2020: -$378.1 thousand | Fiscal year 2019: -$969.2 thousand | Fiscal year 2018: -$1.50 million | Fiscal year 2017: -$15.53 million | Fiscal year 2015: -$41.32 million | Fiscal year 2014: -$23.39 million | Fiscal year 2013: -$18.10 million | Fiscal year 2012: -$12.89 million | Fiscal year 2011: -$3.51 million | Fiscal year 2010: -$5.40 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026